New Considerations for Diabetes in 2008- Pharmacist

  Price  

  Credits  1.5

This product is currently out of stock and unavailable.


Format
The development of type 2 diabetes mellitus (T2DM) involves three different mechanisms: insulin resistance, impaired insulin secretion, and excess production of glucose from the liver. Researchers are constantly seeking new drug therapy targets, and less invasive, more convenient routes of drug administration. As treatment for T2DM becomes more complicated and more clinical experience is gained with the drugs currently available, new issues and considerations inevitably arise. Whether these issues involve new insight into possible drug side effects, changes in glycemic treatment goals, or new thoughts involving our monitoring paradigms, it is in your best interest and your patients’ best interest to stay up-to-date. This article summarizes 6 recent developments in the treatment of T2DM: the link between thiazolidinediones (e.g., Avandia®, Actos®) and bone fracture, the potential for heart attacks and heart failure associated with thiazolidinedione use, recent findings regarding tight glucose control and cardiovascular risk, the potential link between inhaled insulin (Exubera®) and lung cancer, use of the lipid-lowering drug colesevelam (WelCholTM) in patients with T2DM, and the potential benefits and drawbacks of self-monitoring of blood glucose (SMBG) in patients who are not using insulin. Each topic is accompanied by patient discussion points to aid you in your efforts to guide them through these recent developments.

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharm/Nurse Drug Therapy

Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
  • Universal Activity Number:
    Pharmacist : 428-0000-08-011-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

In order to obtain a Statement of Credit, attendees must answer poll questions where presented and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.